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Summary The response of KHT sarcomas to one, two, five or ten daily fractions of 1-(2-chloroethyl)-3-
cyclohexyl-l-nitrosourea (CCNU), with and without misonidazole (MISO), was evaluated using delay of
tumour regrowth as the measure of response. When CCNU was given as 2 dose fractions separated by 24h
rather than as a single treatment, no extra dose was necessary to achieve a particular level of damage,
suggesting a lack of damage repair. With increasing fraction number, however, an increasing total dose of
drug was required to achieve a given effect, presumably to compensate for proliferation. Increasing drug
doses also were readily tolerated (almost twice the LD50/7 for a single dose of CCNU resulted in no deaths
when given in a 10 fraction treatment) indicating a large sparing of normal tissue toxicity when CCNU
treatments were fractionated.
The addition of MISO enhanced the tumour response to CCNU in all treatment schemes. When single
doses of CCNU were combined with 0.5mgg-1 MISO, an enhancement ratio (ER) of - 1.5 was observed.
This ER was maintained for all fractionated treatment schedules including the 10 daily fraction protocol. In
addition, no loss of sensitization with increasing fractionation was observed when a lower dose of 0.2mgg-1
MISO was combined with each of 5 or 10 daily fractions of CCNU. Similar experiments were performed to
test the combination of cyclophosphamide (Cy) and MISO (0.5mgg-1) in the RIF-l tumour; again
chemopotentiation was maintained with increasing fractionation. These results of combined MISO and
fractionated chemotherapy are in contrast to the rapid loss of sensitization observed when MISO is used as a
radiation sensitizer and combined with small doses of X-rays, thus providing in vivo evidence of the
mechanistic difference between the effects of MISO used as a radiation sensitizer or chemopotentiator.
Peripheral white blood cell counts performed on mice receiving 5 daily fractions of CCNU+MISO displayed
no significant enhancement of normal tissue toxicity by MISO. Thus combining MISO with repeated low
dose treatments of a chemotherapeutic agent results in a therapeutic gain.
Over the last few years there has been increasing
interest in potentiating the action of conventional
chemotherapeutic drugs by the addition of a
chemical radiosensitizing agent such as
misonidazole (MISO). There are now many reports,
using different combinations of these drugs and a
variety of mouse tumour models, which indicate a
greater tumour-cell cytotoxicity than that seen in
the dose-limiting normal tissues i.e. a therapeutic
gain has been achieved (for reviews see McNally,
1982; Siemann, 1982a).
As with the initial experimental evaluation of
MISO as a radiation sensitizer, these chemo-
potentiation studies have primarily concentrated on
combinations of single doses of the chemo-
therapeutic agent and sensitizer. While the single
dose radiation studies demonstrated substantial
enhancement ratios (Adams, 1977), when
fractionated irradiations were investigated, the
sensitizing effect of MISO decreased as the X-ray
dose per fraction decreased (Denekamp & Stewart,
1978; Hill and Bush, 1978).
Currently little is known as to whether
chemopotentiation by MISO is affected by drug
treatment fractionation as has been observed for
radiosensitization. This is of some clinical
importance since, although chemotherapy treatment
regimes differ widely according to the agent
involved and the toxicities they produce, many
involve multiple drug exposures. The present study
therefore was undertaken to determine whether a
loss of sensitization, similar to that seen with X-
rays, also occurred when MISO was combined with
fractionated chemotherapy. The combination of 1-
(2-chlorethyl)-3-cyclohexyl-l-nitrosourea (CCNU)
and MISO, was chosen as a model, for detailed
investigation, since it is particularly effective in the
KHT sarcoma (Siemann, 1981, 1982b). Studies
designed to compare the effect of single doses and
fractionated treatments (2, 5 and 10 daily fractions
of CCNU in the absence or presence of MISO) on
the KHT sarcoma were performed. These
investigations therefore were directly comparable to
previously reported sensitization studies combining
fractionated radiotherapy and MISO treatment in
this tumour model (Hill and Bush, 1978). For
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comparison, experiments were also performed to
investigate the response of the RIF-1 tumour to
multiple doses of cyclophosphamide (Cy) and
MISO.
Materials and methods
Mice and tumours
The experiments described were performed using
either the KHT sarcoma (Kallman et al., 1967) or
the RIF-l tumour (Twentyman et al., 1980) in
female C3H/HeJ mice (8-14 weeks old), obtained
from Jackson Laboratories, Bar Harbor, Maine.
KHT cells were prepared from solid tumours by
mechanical dissociation (Thomson & Rauth, 1974)
and passaged in vivo every 2 weeks. RIF-1 tumour
cells were maintained and passaged alternately in
vitro and in vivo as described by Twentyman et al.
(1980). For experiments, 2 x 105 cells were injected
i.m. into the left hind legs of recipient mice. When
the tumours reached 0.2-0.3g in weight, the mice
were randomly allocated to different treatment
groups.
Drug treatments
CCNU was dissolved in absolute ethanol (5 or
O0mgml-1), until just before injection, when it was
diluted 10-fold by the addition of 9ml of a 0.3%
hydroxypropyl cellulose in sterile saline solution to
1ml of the stock, solution. Cy was dissolved in
saline at 2.5, 5 or 10mgmP-'. MISO was prepared
as a 20mgml-1 solution in sterile saline and given
simultaneously with CCNU or Cy in the combined
drug treatments. All injections were administered
i.p. according to animal body wt.
Tumour response
Following treatment, tumour response was assessed
by measuring growth delay. Tumours were
measured three to five times a week, by passing the
tumour-bearing leg through a plastic rod with holes
of increasing diameter. The smallest hole the
tumour-bearing leg would pass through was
recorded and converted to a tumour weight using a
calibration curve (Siemann et al., 1977; Siemann &
Sutherland, 1980). The number of days for each
tumour to grow to 5 times the size at treatment was
then determined. The median time for the tumours
of each group of animals to reach this endpoint
was calculated and plotted against drug dose.
Confidence limits about the median were calculated
using non-parametric statistics (Noether, 1971).
Normal tissue toxicity
Toxicity was assessed by measuring the depression
of white blood cell (WBC) counts in both tumour-
and non-tumour-bearing mice following treatment.
Ten p1 blood samples were taken from the tips of
the tails of unanaesthitized mice and diluted in
10ml saline. Three drops of RBC lysing solution
were added to lyse the red cells and counts were
made on a Coulter Counter and Channelyzer
system (Model C1000). Five mice were used for
each treatment group.
Blood smears also were made, air-dried and
stained with Wright's Giemsa stain. One hundred
cells per slide then were counted and scored as
granulocytes, lymphocytes or monocytes.
Pharmacokinetic determinations
Ten minutes prior to blood collection, mice were
injected with 0.2ml of heparin. Blood was taken
from the thoracic cavity after cutting the aorta and
vena cava. Samples from 2-3 animals were collected
and pooled. Following immediate high speed
centrifugation, the plasma was withdrawn and
frozen in liquid nitrogen.
For analysis 0.5ml plasma was diluted with an
equal volume of HPLC grade acetonitrile and
spiked with a lOpl sample of an internal standard
(Phenytoin, 2mgml-1). After vortexing, centri-
fugation, andfiltration, thesupernatatantwasinjected
into the high pressure liquid-chromatograph
(Waters Associates, Milford, Mass). Reverse phase
HPLC analysis was performed according to the
methods of Lee and Workman (1983). Briefly, the
separation of CCNU was achieved on a Waters
Radical-PAK reverse phase bonded octadecylsilane
(C18) cartridge column by running a two-step
linear gradient starting at 34% acetonitrile in water
changing to 44% acetonitrile in water over 5min
and to 64% acetonitrile in water over another 7min
as previously described (Lee and Workman, 1983).
CCNU was analysed at a wavelength of 254nm by
means of a Waters Associates Model 441 u.v.
absorbance detector.
Results
Figure 1 shows the dose-response curves for the
KHT sarcoma following treatment with one or two
fractions of CCNU, either alone or in combination
with MISO. These experiments were designed such
that the total dose of both drugs remained
constant, whether given as a single dose or as two
equal fractions, separated by 24h. A single curve
can be drawn through the data for treatment with
CCNU alone given as either one or two fractions.
Similarly the data obtained when CCNU and
MISO (a single dose of l.Omgg-1 or two doses of
0.5mgg-1) were combined also fit a single curve.
These results indicate that when CCNU wasMISO CHEMOPOTENTIATION WITH FRACTIONATED CHEMOTHERAPY 511
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Figure 1 Median time to regrow to 5 x the starting
size as a function of CCNU dose for tumours treated
with a single dose (0, 0) or two equal fractions
(A, A) of either CCNU alone (0, A), or CCNU plus
MISO (0, A). MISO was administered as a single
dose of 1.0 mg g - I (0) or as two fractions of
0.5mgg-I (A). Each datum point represents the
median tumour response (±98% confidence limits) on
a group of 7 mice.
administered as two fractions over 24h, the damage
produced was no less than that seen when the
tumours were treated with an equivalent single dose
at time zero. In both instances the ratio of CCNU
doses with and without MISO required to give the
same regrowth time, i.e., the enhancement ratio
(ER), was - 1.8. This value is similar to the ER of
1.9 previously reported for this tumour treated with
single doses of CCNU and 1.Omgg-' MISO
(Siemann, 1982b).
To determine the effect of drug treatment
fractionation on chemopotentiation by MISO, a
fixed dose of MISO (0.5mgg- 1) was combined
with 1, 2, 5 or 10 daily doses of CCNU. Figure 2
shows the single dose and two fraction data. At a
sensitizer dose of 0.5mgg-' the enhancement of
growth delay was a factor of - 1.5 for the single
dose treatment and 1.7 for the two fraction
treatment.
To investigate whether enhanced tumour
responses could be maintained when daily
0.5mgg-1 doses of MISO were combined with
even smaller doses of CCNU per fraction, five and
ten fraction treatments were evaluated. In addition,
for these latter protocols, the effect of reducing the
MISO dose per fraction from 0.5 to 0.2mgg-1 also
was studied. The results of these experiments are
shown in Figure 3. A dose of 0.5mgg-1 MISO
given with each CCNU dose resulted in
enhancement ratios of 1.6 and 1.5 for the five and
ten daily fraction protocols respectively (solid vs
open symbols). When the lower dose of MISO
(0.2mgg-1) was combined with daily doses of
CCNU, enhanced tumour responses to CCNU also
were observed (harlequin symbols). With this dose
of MISO, both fractionation schedules led to ERs
of 1.3-1.4. These values are similar to the
previously published value of 1.3 measured for this
tumour treated with a single dose of 0.25mgg-1
MISO plus CCNU (Siemann, 1982b). At both
sensitizer doses studied the results therefore indicate
no loss of sensitization with fractionation.
The various dose fractionation studies can be
compared by determining an isoeffect curve. This is
illustrated in Figure 4 where the total dose required
for each CCNU fractionation schedule to yield a
regrowth time of 20 days was calculated for both
CCNU alone and CCNU combined with MISO.
The data indicate that MISO potentiates the efficacy
of CCNU not only at large doses per fraction but
also that this potentiation is not lost as the dose
per fraction is decreased.
This lack of a loss of potentiation with drug
fractionation can also be seen in Figure 5. This
figure illustrates the results obtained when a fixed
total dose of 30mgkg-1 CCNU is delivered either
as a single treatment or as two, five, six, eight or
ten equal daily fractions, administered with or
without 0.5mgg-1 MISO accompanying every
dose. When 30mgkg-1 CCNU is subdivided into
five fractions or more, the resulting growth delay
approaches that measured for untreated control
tumours i.e. daily doses of 6mgkg-1 CCNU or less
are insufficient to retard tumour growth
significantly. However, the addition of MISO to
even these low doses of the nitrosourea, which in
themselves are totally ineffective, produced a
significantly enhanced tumour response.
In order to determine whether the observed
potentiation of CCNU by MISO was influenced by
changes in the pharmacokinetics of the
chemotherapeutic agent in the presence of MISO,
CCNU plasma levels were determined in C3H mice
exposed to 20mgkg-1 CCNU alone or
simultaneously combined with 0.2 or 0.5mgg-1
MISO (Table I). CCNU concentrations were
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Figure 2 Dose-response curves for tumours treated with one or two fractions of CCNU with (closed
symbols), or without (open symbols) 0.5mgg-1 MISO. The two fraction data in the right-hand panel are
reproduced from Figure 1. Data shown are the median tumour responses (±98% confidence limits) of groups
of 7 mice. Upward arrows indicate groups in which animals had to be sacrificed before tumour regrowth.
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Figure 3 The response of tumours to five or ten daily
fractions of CCNU alone (A\, C]) or CCNU plus 0.5
(A, *) or or 0.2 (A, 3) mgg-I MISO, plotted as the
median time to regrow to 5 x their original weight
(±98% confidence limits) for groups of 7 mice.
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Figure 4 Isoeffect curves for tumours treated with
fractionated CCNU, administered either alone (0) or
with 0.2 (O) or 0.5 (0) mgg-I MISO accompanying
each dose. The total dose of CCNU which resulted in
tumour regrowth 20 days after treatment is plotted
against fraction number.
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Figure 5 Median time to grow to 5 x starting size
(±98% confidence limits) versus fraction number, for
groups of 7 mice treated with a total dose of
30mgkg-l CCNU, with (0) or without (0)
0.5mgg1 MISO accompanying each fraction.
Table I Effect of MISO on CCNU plasma
pharmacokineticsa
CCNU MISO CCNUplasma concentration
(mgkg 1) (mgg1) at 25min (ugml-l)b
20 0.15+0.02
20 0.2 0.15+0.02
20 0.5 0.24+0.03
'CCNU and MISO were administered
simultaneously.
bData shown are the mean + s.e. of 6-7
determinations each pooling the blood of 2-3 mice.
determined 25min after treatment using the
procedure developed by Lee and Workman (1983).
This time was chosen on the basis of previous
evaluations (Lee and Workman, 1983) which
demonstrated that monitoring the CCNU plasma
concentrations at this fixed time could readily
detect the influence of MISO on the plasma
clearance of the nitrosourea. The data in Table I
indicate that the plasma clearance of CCNU was
reduced somewhat by a MISO dose of 0.5mgg-1
but not significantly affected by a dose of
0.2mgg-1.
To assess normal tissue toxicity, WBC counts
were made on blood samples taken from the tails of
C3H mice. Siemann (1982b) and McNally et al.
(1982) have previously reported a depression in the
white cell count which reached a nadir between
days 2 and 4 following single dose treatment with
CCNU or CCNU plus MISO. Since it was not
known whether fractionation might influence the
time course of this response, blood samples were
taken at 2 or 3 day intervals, from groups of 5
animals, for a total of 26 days following the initial
treatment. Measurements were made following the
five fraction schedule only; each mouse received a
total of 50mgkg-1 CCNU (5 x 10mgkg-1) with or
without 0.2 or 0.5mgg-1 MISO accompanying
each dose. All three treatment schedules produced a
drop in the WBC count over the first 4 days,
followed by a gradual recovery. However, none of
the counts returned to pretreatment levels over the
full three weeks of measurement. MISO did not
significantly enhance the white cell depression
measured at the nadir, although there was a
suggestion that those animals which received the
combined treatment maintained a somewhat lower
WBC count than those animals receiving CCNU
alone. No consistent difference was seen between
the responses of tumour-bearing and non-tumour
bearing mice.
Since white cell depression was maximal between
days 4 and 7, a dose-response relationship for the
five fraction regimen was measured on day 5, after
the completion of treatment. Figure 6 shows total
WBC counts for animals treated with a range of
CCNU doses with or without 0.2 or 0.5mgg-1
MISO accompanying each dose. There was no
consistent enhancement of CCNU-induced WBC
toxicity by MISO.
Differential cell counts of granulocytes,
lymphocytes and monocytes revealed that the cells
primarily affected by the treatment where the
peripheral granulocytes. Four days after the start of
treatment, the depression in WBC count was almost
entirely due to granulocyte depletion and no
difference could be detected between samples from
animals which had received CCNU alone or CCNU
plus MISO.
Growth delay experiments also were performed
to assess the response of the RIF-1 tumour to
repeated daily doses of Cy with or without
0.5mgg-1 MISO. Complete dose response curves
were obtained for protocols combining MISO with
a range of 1, 2, 5 or 10 daily dose fractions of Cy.
From these the ERs measured at a regrowth time
of 15 days, were calculated (Table II). As was seen
with CCNU, the degree of chemopotentiation
measured remained unchanged whether MISO was
combined with a single fraction or multiple daily
dose fractions of Cy.
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Figure 6 Total white blood cell counts as a function
of CCNU dose, measured after the final treatment in a
five fraction regime. Groups of 5 mice were treated
with varying doses of CCNU either alone (0) or with
0.2 (O) or 0.5 (a) mgg-1 MISO accompanying each
dose.
Table II The enhancing effect of 0.5mgg-1
MISO on the cytotoxicity of cyclophosphamide
in the RIF-1 tumour, measured at a regrowth
time of 15 days.
Treatment Enhancement ratio
Single dose 1.4
2F 1.4
5F 1.5
lOF 1.3
Discussion
That nitroimidazole radiation sensitizers can
effectively increase the cytotoxicity of several
chemotherapeutic agents is now well established
(see McNally, 1982; Siemann, 1982a, 1984; Millar,
1982, for reviews). While most of the in vivo data
concern tumour responses to large single doses of
drugs, several studies have indicated that
sensitization would not decrease with decreasing
doses of the chemotherapeutic drug (Twentyman,
1981; Law et al., 1981; Hirst et al., 1982; Siemann,
1984). It also has been suggested that the
therapeutic gain should be highest with low doses
of chemotherapy, where MISO appears not to
enhance bone marrow toxicity. Therefore, although
clinical chemotherapy regimes are very varied and
may or may not involve repeated drug doses, it was
considered of interest to investigate whether both
chemopotentiation and a therapeutic advantage
could be maintained when treatments were
extended to multiple drug exposures. The
combinations of CCNU plus MISO and Cy plus
MISO were chosen for evaluation because of their
proven efficacy in single dose studies (for review see
McNally, 1982).
The results presented here indicate that the
potentiation of CCNU cell killing in the KHT
sarcoma, achieved by a single administration of
MISO, can be maintained at the same level with
multiple fractions. This enhanced response was
maintained with low doses per fraction of both
agents. Significant sensitization was achieved with a
MISO dose as low as 0.2mgg-t i.e. closer to
clinically achievable levels than the doses generally
employed in experimental investigations. A
substantial delay in tumour regrowth also was seen
when MISO was added to a low dose fractionated
CCNU regime, which in itself produced no
detectable antitumour activity (Figure 5).
The initial split-dose studies (Figure 1), showed
that approximately equal levels of damage were
produced by a particular drug dose whether it was
delivered as a single treatment or as two equal
fractions separated by 24h, suggesting the absence
of any repair during this interval. As treatments
were extended to five and ten fractions (Figure 3)
extra dose was required to produce the same
tumour effect, but this was probably due to
proliferation. The tumours continue to grow
throughout the treatment period, since cell death
and removal does not occur at the time each dose is
administered. Due to the rapid growth of the KHT
sarcoma, (volume doubling time 1.5-2.5 days),
fractionation could not be extended beyond the 10
day treatment period employed. At many of the
dose levels used in both the five and ten fraction
experiments, no tumour regression could be
detected by the end of the course of treatment,
although ultimately shrinkage did occur, followed
by regrowth. Clinically, lack of tumour response
during treatment is frequently used as a reason for
terminating therapy with the drug in question.
Clearly in this experimental situation, lack of
responsiveness during treatment did not indicate
lack of treatment effectiveness and would have
proved a poor prognostic indicator.MISO CHEMOPOTENTIATION WITH FRACTIONATED CHEMOTHERAPY 515
As well as the dose sparing effect observed in the
tumour, a large sparing of lethal toxicity also was
seen with increasing fractionation. Using mice of
the same sex and strain as those in the present
study, Siemann (1981), previously reported an
LD50/7 value of 46.4 (44.4-48.6)(95% confidence
limits)mgkg-1 CCNU, which was reduced to 38.8
(36.9-40.8)mgkg- 1 on combination with 0.5mgg-1
MISO. In the present study greatly increased doses
of drug were administered without approaching the
LD50/7. No deaths occurred with a dose of
60mgkg- 1 CCNU delivered in five fractions, or
90mgkg-1 in ten fractions i.e. practically double
the dose which proved lethal to 50% of the animals
when given as a single treatment. Similarly, when
MISO was added to the treatment protocol, higher
total doses of CCNU were tolerated when they
were fractionated; 40 and 50mgkg- 1 in five
fractions and 50 and 80mgkg-1 in 10 fractions for
0.5 and 0.2mgg- 1 MISO respectively. Since the
doses did not extend to levels where any lethality
was encountered, no estimate could be made of the
increases in LD50 values resulting from the
different protocols. However, the available data
indicate that the increase in the tolerated dose is at
least as large as the increase in the dose required to
produce the same tumour effect. This suggests that
there is no loss of therapeutic gain in progressing
from one to ten fractions.
Myelosuppression is the primary dose-limiting
toxicity of CCNU in man, which is manifest as a
delayed leucopenia. Therefore, to further consider
the question of therapeutic gain, we measured the
total white cell count following treatment with
CCNU with or without MISO, delivered in a five
fraction protocol. The data illustrated in Figure 6,
measured at the time of peak white cell depression,
did not indicate any significant enhancement of
CCNU-induced WBC toxicity by MISO, again
suggesting no loss of therapeutic gain.
Two previously published studies have included
information on the effects of five daily fractions of
Cy and MISO. Twentyman (1981) considered just
two dose levels of Cy and measured the growth
delay resulting from treatment with and without
MISO (0.33mgg-1) in the RIF-l and KHT
sarcomas. Single dose experiments with this dose of
MISO produced only a small enhancement of Cy
response in both tumour systems. On extending the
treatments to five fractions an increase in growth
delay was measured at the higher of the two Cy
doses for the RIF-1 tumour, but toxicity was very
high at this drug level, even without the addition of
MISO. However, the response of the KHT tumour
was significantly enhanced at both Cy doses.
Extrapolation of the data suggested an ER of 1.5
which was significantly greater than the
enhancement achieved by a single treatment. In a
similar experiment, again using the RIF-l tumour,
Law et al. (1981) reported an ER of 1.5 to 1.7 for
the five fraction treatment with 0.3mgg-1 MISO.
No data were available for single dose treatments
with this level of MISO, and no measurement of
normal tissue toxicity was made. These data
together with the current results which are
summarized in Table II, suggest that MISO can
markedly increase the effectiveness of low as well as
high dose Cy. Mulcahy et al. (1982) investigated the
effectiveness of combining 0.7mgg-1 MISO with
each of three daily doses of BCNU
(10mgkg-1day-1) but no enhancement of growth
delay was measured. Clearly more data are
necessary to allow a thorough evaluation of which
drug combinations are most likely to result in a
favorable therapeutic response when delivered in a
multiple low dose treatment regime.
The results presented here for the potentiation of
CCNU damage by MISO are in direct contrast to
the data obtained when MISO was tested as a
radiation sensitizer (Hill & Bush, 1978; Denekamp
& Stewart, 1978). In these studies, large
enhancement ratios were measured for single dose
treatments, however, when the radiation dose was
fractionated, the sensitizing effect of the drug
decreased as the radiation dose per fraction
decreased. Similarly, breathing carbogen (95%
02+5% CO2) was found to sensitize tumours to
the effects of large single doses of radiation (by
decreasing the hypoxic fraction), but again,
sensitization decreased with fractionation and
decreasing doses of radiation (Hill & Bush, 1977).
The current data emphasize that the mechanism by
which MISO potentiates the action of CCNU must
be different from that by which both it and oxygen
act as radiation sensitizers.
Several reasons have been put forward to explain
the loss of radiation sensitization with decreasing
dose per fraction. At low doses of radiation, the
oxygen enhancement ratio (OER) has been found
to be reduced (Palcic et al., 1982). This would tend
to imply that multiple small fractions should be
more effective than large single doses of radiation,
since the protected status of the hypoxic cells would
be reduced, this would also reduce the degree of
radiosensitization which be achieved. In addition,
since it is the fully oxygenated radiosensitive cells
within a tumour which will dominate its response
when low radiation doses are used, the natural
process of reoxygenation occuring between
successive fractions may also serve to reduce the
importance of hypoxic cells and therefore the
benefit that might be gained by hypoxic cell
sensitizers such as MISO. This is further supported
by the observation that MISO affects the final, but
not the initial slope of a radiation survival curve i.e.
the # but not the the a component of the linear516 S.A. HILL & D.W. SIEMANN
quadratic cell survival model (Palcic et al., 1983).
Since the a term dominates at low radiation doses,
these data would again imply that MISO should be
more effective at high radiation doses.
Several studies have suggested that MISO is a
more efficient chemosensitizer when combined with
low doses of the chemotherapeutic agent
(Twentyman, 1981; Law et al., 1981; Hirst et al.,
1982; Mulcahy et al., 1982). It also has been noted,
both in vitro and in vivo, that chemopotentiation
frequently, though not always, occurs as a
reduction or loss of the shoulder on the dose
response curve, with little change in the final slope
(Stratford et al., 1980; Siemann et al., 1984; Roizin-
Towle & Hall, 1981). This suggested that
fractionation might prove successful. The data
presented here have indicated a cumulative effect of
repeated low doses, with no evidence of repair
processes occurring between subsequent fractions.
Potentiation of CCNU damage appears to occur
with every treatment (Figure 4), even when the
chemotherapy alone is totally ineffective in
retarding tumour growth (Figure 5). One
explanation may be that chemosensitization occurs
at least to some extent at oxygen levels above those
required for radiobiological hypoxia. If this were
the case a large population of cells would be at risk
to be sensitized and hence even at the lowest
CCNU dose per fraction evaluated this
subpopulation could still determine the overall
tumour response, therefore no loss of
chemopotentiation with fractionation would be
expected. In support of this view, in vitro studies
have indicated that chemopotentiation, although
reduced in magnitude, can be demonstrated at
relatively high oxygen tensions despite the KM value
for chemopotentiation by MISO being equal to that
for MISO cytotoxicity (Mulcahy, 1984). In addition
it seems clear that, while hypoxic cells are necessary
for chemopotentiation (McNally, 1982; Brown,
1982; Wheeler et al., 1984; Siemann, 1984) this
effect is not restricted to the fraction of
radiobiologically hypoxic tumour cells (Siemann,
1982a). Finally, if modification of chemotherapeutic
agent activity occurred at oxygen tensions above
those associated with radiobiological hypoxia this
also could play a role in the enhanced normal tissue
toxicities associated with drug-sensitizer
combinations.
Possible mechanisms for chemopotentiation have
been extensively reviewed elsewhere (Brown, 1982;
Millar, 1982; McNally, 1982; Siemann, 1982a, 1984)
and will not be addressed in detail here. It is
possible however, to consider the importance of
modification of cytotoxic drug pharmacokinetics by
MISO in the context of the present experiments.
Considerable data now exist to indicate that
sensitizers can alter the pharmacokinetics of a
number of chemotherapeutic agents (Hinchliffe et
al., 1983; Lee & Workman, 1983). While failing to
account for all the chemopotentiation results,
pharmacokinetic changes are involved when
chemotherapeutic agent efficacies are enhanced in
vivo by large sensitizer doses (for review see
Siemann, 1984). Lee and Workman (1983) observed
that the plasma clearance of CCNU was reduced as
the MISO dose was increased, with a threshold
MISO dose of approximately 0.3mgg-1. The
current results (Table I). which indicate that a
MISO dose of 0.5mgg-1 reduced the clearance of
CCNU while a 0.2mgg-1 dose had no effect, are
consistent with those previous findings. The
0.2mgg-1 dose was sufficient, however, to achieve
chemopotentiation in a fractionated dose protocol
(Figures 3 and 4) suggesting that chemopotentiation
can occur in the absence of a pharmacokinetic
effect.
In summary, the present results indicate that
unlike the loss of sensitization seen when MISO is
added to fractionated radiation, no loss of
potentiation occurred with fractionated CCNU plus
MISO. In addition, repeated low dose treatments
with both agents did not appear to increase the
normal tissue toxicity above that achieved with a
single high dose treatment, suggesting no loss of
therapeutic benefit with fractionation. Further
fractionated treatments aimed at determining the
effectiveness of other drug combinations
particularly with clinically relevant doses of MISO
and utilizing several tumour models are indicated.
Nevertheless, the benefits seen in this study suggest
that MISO might be successfully added to repeated
low dose chemotherapy treatments.
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